FDA Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Thrombocytopenia
Hollis-Eden Pharmaceuticals Reports Publication of Results Demonstrating the Ability of NEUMUNE to Increase Survival in a Primate Model of Lethal Radiation Injury
March 15th, 2007
Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) reported that the Company's study results demonstrating that its Acute Radiation Syndrome (ARS) drug candidate, NEUMUNE(R) (HE2100), significantly improved survival in clinically unsupported rhesus monkeys with radiation-induced myelosuppression, is being published in the April 2007 issue of International Immunopharmacology and is now available on-line at http://dx.doi.org/10.1016/j.intimp.2006.12.005. The Company believes the published data represent the first instance where a compound administered as a single agent after exposure favorably affected survival in lethally irradiated, clinically unsupported non-human primates. In the event of a...
Source: FDA Law Weekly (2007-03-15)
|
